Skip to main content
Fig. 4 | Immunity & Ageing

Fig. 4

From: Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine

Fig. 4

T-cell responses to pooled peptides of SARS-CoV-2 variant spike proteins. PBMCs were stimulated with pooled peptides of SARS-CoV-2 variant spike proteins, including the following pools: A B.1.1.7 mutation; Alpha variant, B B.1.351 mutation; Beta variant, or C B.1.617.2 mutation; Delta variant. The frequency of CD4 or CD8 T cells expressing IL-17A, IFN-γ or FasL before (2CoVac) (N = 6) and 4 weeks after boosting with ChAdOx-1 (2CoVac + ChAd) (N = 10) and BNT162b2 (2CoVac + BNT) (N = 10) was determined using intracellular immunofluorescence staining and flow cytometry. Individual data points are shown. Lines represent the median with the interquartile range. The Mann–Whitney U test was used for comparison. ns indicates no significant difference (p > 0.05), * p ≤ 0.05, ** p ≤ 0.01, and*** P < 0.0005

Back to article page